1. Shared and unique transcriptomic signatures of antidepressant and probiotics action in the mammalian brain.
- Author
-
Rayan NA, Aow J, Lim MGL, Arcego DM, Ryan R, Nourbakhsh N, de Lima RMS, Craig K, Zhang TY, Goh YT, Sun AX, Tompkins T, Bronner S, Binda S, Diorio J, Parent C, Meaney MJ, and Prabhakar S
- Subjects
- Animals, Mice, Male, Female, Disease Models, Animal, Fluoxetine pharmacology, Mice, Inbred C57BL, Bupropion pharmacology, Depression genetics, Depression drug therapy, Depression metabolism, Probiotics pharmacology, Transcriptome genetics, Brain metabolism, Brain drug effects, Antidepressive Agents pharmacology, Depressive Disorder, Major genetics, Depressive Disorder, Major metabolism, Depressive Disorder, Major drug therapy
- Abstract
Understanding the shared and divergent mechanisms across antidepressant (AD) classes and probiotics is critical for improving treatment for mood disorders. Here we examine the transcriptomic effects of bupropion (NDRI), desipramine (SNRI), fluoxetine (SSRI) and a probiotic formulation (Lacidofil®) on 10 regions across the mammalian brain. These treatments massively alter gene expression (on average, 2211 differentially expressed genes (DEGs) per region-treatment combination), highlighting the biological complexity of AD and probiotic action. Intersection of DEG sets against neuropsychiatric GWAS loci, sex-specific transcriptomic portraits of major depressive disorder (MDD), and mouse models of stress and depression reveals significant similarities and differences across treatments. Interestingly, molecular responses in the infralimbic cortex, basolateral amygdala and locus coeruleus are region-specific and highly similar across treatments, whilst responses in the Raphe, medial preoptic area, cingulate cortex, prelimbic cortex and ventral dentate gyrus are predominantly treatment-specific. Mechanistically, ADs concordantly downregulate immune pathways in the amygdala and ventral dentate gyrus. In contrast, protein synthesis, metabolism and synaptic signaling pathways are axes of variability among treatments. We use spatial transcriptomics to further delineate layer-specific molecular pathways and DEGs within the prefrontal cortex. Our study reveals complex AD and probiotics action on the mammalian brain and identifies treatment-specific cellular processes and gene targets associated with mood disorders., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF